Walk Vascular offers JETi peripheral systems that will help remove intravascular clots called a thrombus, which may minimise blood flow and lead to serious complications for patients
Abbott has acquired medical device company Walk Vascular. (Credit: Abbott)
Healthcare technology company Abbott has acquired a commercial-stage medical device firm Walk Vascular for an undisclosed sum.
Established in 2010, Walk Vascular offers a minimally invasive mechanical aspiration thrombectomy system for the removal of peripheral blood clots.
Abbot will include Walk Vascular’s peripheral thrombectomy system into the company’s existing endovascular product portfolio.
Walk Vascular offers JETi peripheral thrombectomy system and a next-generation JETi AIO (all in one) peripheral thrombectomy system.
Both unique aspiration systems are designed to remove intravascular clots called a thrombus, which may minimise blood flow and lead to serious complications for patients.
The JETi systems helps to break-up and remove clots from the peripheral vascular system while minimising the risk of dislodged clots, said the company. Both systems are supported by real-world clinical experiences.
At present, Walk Vascular is recruiting up to 250 patients in the JETi Registry in the US and Europe.
Walk Vascular already secured 510(k) clearance from the US Food and Drug Administration (FDA) for both the JETi peripheral thrombectomy systems for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature.
In addition, the systems have CE marks in Europe and approvals in other countries.
Abbott’s vascular business senior vice president Julie Tyler said: “The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care.
“Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”
In August this year, Abbott secured FDA approval for its Amplatzer Amulet left atrial appendage (LAA) occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.